Relief Therapeutics Holding Past Earnings Performance
Past criteria checks 0/6
Relief Therapeutics Holding's earnings have been declining at an average annual rate of -64.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 68.9% per year.
Key information
-64.2%
Earnings growth rate
-55.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 68.9% |
| Return on equity | -85.6% |
| Net Margin | -1,378.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Relief Therapeutics Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 6 | -81 | 25 | 3 |
| 31 Mar 23 | 6 | -66 | 25 | 8 |
| 31 Dec 22 | 6 | -51 | 24 | 12 |
| 30 Sep 22 | 6 | -49 | 21 | 17 |
| 30 Jun 22 | 7 | -47 | 19 | 21 |
| 31 Mar 22 | 5 | -41 | 17 | 20 |
| 31 Dec 21 | 3 | -35 | 15 | 19 |
| 30 Sep 21 | 2 | -33 | 12 | 21 |
| 30 Jun 21 | 0 | -31 | 8 | 22 |
| 31 Mar 21 | 0 | -19 | 7 | 18 |
| 31 Dec 20 | 0 | -8 | 5 | 14 |
| 30 Sep 20 | 0 | -3 | 5 | 7 |
| 30 Jun 20 | 0 | 1 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 2 | 0 |
| 31 Dec 19 | 0 | -7 | 1 | 0 |
| 30 Sep 19 | 0 | -4 | 1 | 0 |
| 30 Jun 19 | 1 | -1 | 1 | 0 |
| 31 Mar 19 | 1 | -1 | 1 | 0 |
| 31 Dec 18 | 1 | 0 | 1 | 0 |
| 30 Sep 18 | 0 | -1 | 1 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -3 | 1 | 0 |
| 31 Dec 17 | 0 | -3 | 2 | 0 |
| 30 Sep 17 | 0 | -10 | 2 | 0 |
| 30 Jun 17 | 0 | -18 | 3 | 0 |
| 31 Mar 17 | 0 | -17 | 2 | 0 |
| 31 Dec 16 | 0 | -17 | 2 | 0 |
Quality Earnings: V6M1 is currently unprofitable.
Growing Profit Margin: V6M1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: V6M1 is unprofitable, and losses have increased over the past 5 years at a rate of 64.2% per year.
Accelerating Growth: Unable to compare V6M1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: V6M1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: V6M1 has a negative Return on Equity (-85.61%), as it is currently unprofitable.